A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1999 participants.
Also called NCT01715818
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,999 participants
- Sponsor
- Registry
-
NCT01715818 -
2012-000671-16
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Austria, Canada, Chile, Colombia, Czechia, Estonia, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Poland, Romania, Russia, South Africa, South Korea, Spain, Sweden, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01715818. Randomized; double masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2013-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
- Condition
- Cardiovascular Disease, Diabetes Mellitus Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- aleglitazar
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01715818- Content hash
eec8d0dcc00da535f1bdacc4dfaa6416b9484910dfd5d4e1f6b49bf581f47119